Fig. 1From: Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age populationFlowchart of study participants. From 470 patients treated with anti-CGRP MAbs, 426 were at working age. Of these, 256 participants had complete data, of which 57.8% (148/256) were employed at both M0 and M3Back to article page